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ABSTRACT 
Objective: Diabetic peripheral neuropathy is the most common long term complications associated with reduced nerve conduction and blood flow. 
The present study was designed to investigate the effect of oral supplementation of α-lipoic acid (600 mg/day) on peripheral, sensory and motor 
nerve conduction and glycaemic control in type 2 diabetes mellitus with peripheral neuropathy. 
Methods: A total of 20 patients were enrolled in this study, then randomly allocated to two groups control (n=10) and intervention group (n=10). 
Patients in control group received only oral hypoglycaemic treatment and in intervention group received α-lipoic acid (600 mg/day) oral 
supplementation along with their oral hypoglycaemic treatment for a period of 3 months. Nerve conduction and glycaemic control were measured 
at the base line and at the end of 3 months by using specific methods. 
Results: In intervention group α-lipoic acid supplementation significantly improves 6 of 15 electrophysiological parameters of nerve conduction. 
Distal latency of peroneal (mean ± SD 5.13 ± 0.52 vs 4.92±0.55; p<0.02), median (mean ± SD 3.66 ± 0.76 vs 3.53±0.63; p<0.03) & ulnar motor nerves 
(mean ± SD 2.91 ± 0.32 vs 2.82±0.36; p<0.01), and Nerve Conduction Velocity of peroneal (mean ± SD 42.0 ± 3.07 vs 43.4±2.13; p<0.03), median 
(mean ± SD 51.4 ± 3.31 vs 52.2±3.59; p<0.01) & ulnar motor nerves (mean ± SD 51.0 ± 5.84 vs 52.1±5.46; p<0.03) shows significant improvement. 
Conclusion: Oral supplementation of α-lipoic acid was found to be effective in improving motor nerve conduction of upper and lower extremities in 
patients with diabetic peripheral neuropathy. 
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INTRODUCTION  
About half of the type 2 diabetes mellitus patient population is 
suffering from peripheral neuropathy and it is one of the long term 
complications in these patients [1]. It is associated with reduced nerve 
conduction and blood flow [2]. Diabetic neuropathy is defined as a 
condition of peripheral nerve dysfunction in people with diabetes after 
exclusion of other causes, which lead to both somatic and autonomic 
nerve dysfunction [3, 4]. The peripheral neuropathy detected by 
electrophysiological testing or by quantitative assessment of vibratory 
and thermal sensitivity [5, 6, 7]. Evidence suggests that oxidative 
stress resulting from enhanced free radical formation and/or defects 
in antioxidant defence is implicated in the development of various 
disorders, including neurodegenerative diseases [8] and diabetic 
complications [9.10]. Oxidative stress is linked with development of 
apoptosis in neurons and supporting glial cells. So it could be unifying 
mechanism that leads to nerve dysfunction in diabetes [11, 12]. 
Treatment with a-lipoic acid, a potent lipophilic free radical scavenger 
[13], results in prevention of neurovascular abnormalities associated 
with experimental diabetic neuropathy [14]. 
Though numerous animal studies have been reported on its 
beneficial effects on diabetes neuropathy, only limited clinical data 
are available concerning its potential effects, especially on Indian 
population. The present study was, therefore, aimed to investigate 
the effect of α-lipoic acid on nerve conduction and glycaemic control 
in diabetic peripheral neuropathy. 
MATERIALS AND METHODS 
Study design and patients  
A randomized open label controlled trial include 20 patients divided 
into two groups, control (n=10) and intervention group (n=10). The 
study was conducted at S. P. Institute of Neurosciences, Solapur, 
Maharashtra, India from June 2007 to January 2008. All subjects 
gave written, informed consent, which was approved by the 
Institutional Review Board, JSS College of Pharmacy, Ootacamund, 
Tamil Nadu, India. Type 2 diabetes mellitus patients with stage 2 
peripheral nephropathy of either sex, aged between 40 to 65 years, 
receiving oral hypoglycaemic agents, with duration of diabetes ≥ 10 
years and HbA1C ≤ 10% were enrolled in the study. None of the 
patients were on antioxidant supplementation. Patients with type 1 
diabetes, juvenile diabetes, pregnant women and lactating mothers, 
voluntary withdrawals and patients with any significant hepatic and 
renal dysfunction were excluded. The assessment of peripheral 
neuropathy consisted first in evaluating the clinical stage: stage 0, no 
functional signs or clinical abnormalities; stage 1, presence of mild 
neuropathy, revealed by sensory signs and/or symptoms, and/or 
absence of at least one tendon reflex; stage 2, severe neuropathy 
with motor deficit or trophic disorders unrelated to arterial disease, 
infection, or traumatic processes.  
Patients were randomized by using computer assisted randomization 
procedure and assigned to control (n=10) and intervention group 
(n=10). Control group received only oral hypoglycaemic agent, 
whereas, intervention group received α-lipoic acid oral 
supplementation (600 mg/day) along with oral hypoglycaemic agent 
for a period of 3 months. The demographic characteristics were 
collected on standard data collection form by face to face interview. 
Primary outcome of the study was assessment of distal latency (DL), 
amplitude & nerve conduction velocity (NCV) for electrophysiological 
evaluation of the upper and lower extremities and secondary outcome 
was fasting plasma glucose (FPG), 2 hours post-load of oral glucose 
tolerance test (OGTT) & HbA1c level and were determined for 
glycaemic control. All the parameters were measured at the baseline 
and at the end of 3 months study. 
Glycaemic control 
Blood samples were obtained after at least 10 hours overnight fast. 
Plasma glucose concentrations & 2 hours post-load of oral glucose 
tolerance test (OGTT) were determined by using an enzymatic kit 
(glucose oxidase). HbAlc values were determined using Nycocard kit 
and Nycocard Reader II (Axis-Shield PoC AS). 
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Electrophysiological evaluation  
Electrophysiological evaluation were performed by measuring the 
median, ulnar & peroneal motor nerve and median, ulnar & sural 
sensory nerve conduction by using RMS EMG EP Mark II, version 1.1, 
(Recorder and Medicare System, India). Stimulating electrode (10 
mm), recording electrode (surface electrode, 20 mm), and ground 
electrode (round ground electrode, 20 mm) were used for all the 
stimulation and recordings. Lower and upper filter frequencies were 
2 Hz to 10 kHz for the motor nerve studies and 2 Hz to 3 kHz for the 
sensory nerve studies. Negative peak amplitude and peak-to-peak 
amplitude measurements were done for the motor and sensory 
response respectively. Peroneal nerve surface stimulation was 
performed at ankle (distal site) and near the knee (proximal site). 
Surface recording electrodes were used with active electrode over the 
belly of the extensor digitorum brevis muscle and the reference 
electrode was distal to active electrode over the muscle tendon. 
Ground electrode was placed between distal site and recording 
electrodes. Median nerve surface stimulation was performed at wrist 
(distal site) and elbow (proximal site). Surface recording electrodes 
were used with active electrode over the belly of Abductor Pollicis 
Brevis and the reference electrode was over the tendon of this muscle. 
Ground electrode was placed over the dorsum of the hand. Ulnar nerve 
surface stimulation was placed at the wrist (distal site) and above the 
ulnar groove at the elbow (proximal site). Surface recording electrodes 
were used with active electrode over the belly of Abductor digiti V 
muscle with a reference electrode distal to active electrode. Ground 
electrode was placed over the dorsum of the hand. 
Median nerve surface stimulation was performed at wrist. Surface 
recording electrodes were used with active electrode over the 
proximal interphalangeal joint of second digit and the reference 
electrode was over the distal Phalanx of the same digit. Ground 
electrode was placed over the dorsum of the hand. Ulnar nerve 
surface stimulation was performed at wrist. Surface recording 
electrodes were used with active electrode over the proximal 
interphalangeal joint of fifth digit and the reference electrode was 
over the distal Phalanx of the same digit. Ground electrode was 
placed over the dorsum of the hand. Sural nerve surface stimulation 
was performed distal to lower border of bellies of the 
gastrocnemius. Surface recording electrodes were used with active 
electrode placed between the lateral malleolus and the Achilles 
tendon at the malleolar level with the reference electrode distal to 
active electrode. Ground electrode was placed between stimulating 
and recording electrodes. 
Statistical Analysis  
Statistical analysis was performed by using GNU PSPP version 0.7.5-
g70514b software. Data are presented as mean± SD or geometric 
mean (95% CI). Differences between baseline and 3 months values 
within the groups were checked by paired Student’s t test, p value 
less than 0.05 was considered significant.  
 
Table 1: Demographic, anthropometric and life style characteristic of study population 
 Variables Control group Intervention group 
Age (years) 55.7±8.1 54.7 ±8.0 NS 
Sex (Male/Female) 8/2 7/3 
Duration of disease (years) 11.5±3.5 13.5±8.7 
Body Mass Index (kg/m2)  
NS 




Alcoholic 4 3 
Smoker 2 2 
Vegetarian/Non vegetarian 4/6 2/8 
Values are given as mean ± S.D (*p≤0.05, NS-Not Significant) 
 
Table 2: Effect of α-lipoic acid on electrophysiological parameters of nerve conduction 
Parameters Control group (n=10) Intervention group (n=10) 
Baseline 3 months p value Baseline 3 months p value 
Electrophysiological parameters 
Peroneal Motor Nerve 
DL 3.55±0.75 3.77±0.69 0.11 5.13±0.52 4.92±0.55 0.02* 
Amplitude 3.55±1.94 3.61±2.11 0.87 3.84±2.11 4.38±2.44 0.15 
NCV 42.4±6.75 43.1±7.25 0.48 42.0±3.07 43.4±2.13 0.03* 
Median Motor Nerve 
DL 3.41±0.68 3.33±0.64 0.17 3.66±0.76 3.53±0.63 0.03* 
Amplitude 9.19±2.70 8.67±2.61 0.17 7.83±3.23 8.45±3.52 0.07 
NCV 52.2±3.90 51.9±2.94 0.90 51.4±3.31 52.2±3.59 0.01* 
Ulnar Motor Nerve 
DL 2.78±0.64 2.67±0.72 0.18 2.91±0.32 2.82±0.36 0.01* 
Amplitude 8.98±3.87 8.56±3.23 0.37 9.83±2.55 9.20±1.83 0.22 
NCV 53.2±4.05 53.1±4.05 0.91 51.0±5.84 52.1±5.46 0.03* 
Median Sensory Nerve 
DL 2.58±0.74 2.74±0.44 0.39 3.00±0.32 2.90±0.30 0.09 
Amplitude 14.6±10.0 15.7±0.77 0.64 17.5±3.32 18.2±3.48 0.39 
Ulnar Sensory Nerve 
DL 2.03±0.26 2.21±0.37 0.13 2.88±0.18 2.27±0.19 0.18 
Amplitude 11.6±3.10 13.5±6.02 0.30 10.7±3.02 10.8±2.58 0.95 
Sural Sensory Nerve 
DL 3.01±0.94 2.88±0.81 0.63 2.94±0.51 2.97±0.72 0.83 
Amplitude 18.3±7.95 16.6±6.66 0.64 15.8±9.22 16.4±9.24 0.22 
Values are given as mean ± S.D (*p≤0.05, NS-Not Significant) 
DL, distal latency; NCV, nerve conduction velocity 
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Demographic characteristics of the patients enrolled in this study 
are summarised in Table 1. Out of 14 patients in the control group, 2 
relocate to other place for job and 2 discontinued for personal 
reasons. Of the 13 intervention patients, 2 were lost during follow up 
and 1 discontinued for personal reasons. In total, data for 10 
patients on control group and 10 patients for intervention group 
were used for the analysis at the end of three months. Control group 
patients had mean age of 55.7±8.1 years and mean duration of 
diabetes 11.5±3.5 years. Whereas intervention group patients had a 
mean age of 54.7±8.0 years and duration of diabetes 13.5±8.7 years. 
Body mass index was higher in both the groups. 
Electrophysiological evaluation  
Table 2 shows effect of α-lipoic acid on electrophysiological 
parameters of nerve conduction in both the groups. In intervention 
group α-lipoic acid supplementation significantly improves 6 of 15 
electrophysiological parameters of nerve conduction. Distal latency 
of peroneal (mean ± SD 5.13 ± 0.52 vs 4.92±0.55; p<0.02), median 
(mean ± SD 3.66 ± 0.76 vs 3.53±0.63; p<0.03) & ulnar motor nerves 
(mean ± SD 2.91 ± 0.32 vs 2.82±0.36; p<0.01), and Nerve Conduction 
Velocity of peroneal (mean ± SD 42.0 ± 3.07 vs 43.4±2.13; p<0.03), 
median (mean ± SD 51.4 ± 3.31 vs 52.2±3.59; p<0.01) & ulnar motor 
nerves (mean ± SD 51.0 ± 5.84 vs 52.1±5.46; p<0.03) shows 
significant improvement. 
Glycaemic control  
Table 3 shows the effect of FPG, OGTT, and HbA1c at baseline 
and after three month supplementation with alpha lipoic acid in 
both control and intervention groups. The fasting plasma glucose 
(FPG) level in control and intervention group at base line and 
after three months supplementation showed no significant 
change (p ≥ 0.05). The oral glucose tolerance test (OGTT) in 
control and intervention groups at base line and after three 
months supplementation was 143±15 & 170±50 mg/dl and 174± 
24 & 169±24 mg/dl respectively. The Glycosylated haemoglobin 
(HbA1c) percentage in control and intervention at base line and 
after three months supplementation was 8.0±0.8 & 8.1±0.7 and 
7.9±0.6 & 7.6±0.4 respectively. None of these values showed 
significant change between the groups. 
 
Table 3: Effect of α-lipoic acid on glycaemic index in both control and intervention group 
Parameters Control group (n=10) Intervention group (n=10) 
 Baseline 3 months Baseline 3 months 
Glycaemic Index 
FPG (mg/dl) 108±17 114±21 122±27 NS 120±28
OGTT (mg/dl) 
NS 
143±15 170±50 174±24 NS 169±24
HbA1c (%) 
NS 
8.0±0.8 8.1±0.7 7.9±0.6 NS 7.6±0.4NS 
Values are given as mean ± S.D (NS-Not Significant), FPG- fasting plasma glucose, OGTT-Oral Glucose Tolerance Test, HbA1c- Glycosylated 
haemoglobin, mg/dl- milligram/decilitre, %- percentage  
 
DISCUSSION 
In this present study electrophysiological parameters revealed more 
pronounced abnormalities in lower-extremity, particularly in the sural 
nerves compared to upper extremity at the baseline and there were no 
significant differences in electrophysiological parameters among both 
the groups with respect to age, gender and duration of disease. Since it is 
a prospective randomised control study, the baseline variation in 
covariate distribution was minimized which is the major strength in this 
study. The placebo effect attributed to open label design and relatively 
small sample size were the limitations of this study.  
Sensory fibre defects were observed in the upper (median and 
ulnar) and lower (sural) extremity distal nerves, in particular the 
peroneal and the sural nerves, which were found to be the most 
significant abnormalities among the patients. These findings are 
similar to previous reported study [15]. Nerve conduction velocity 
was found to be significantly increased in the intervention group, 
which was similar to the previous findings, suggesting that the 
improvement in neurovascular changes were induced by improving 
oxygen free radical scavenging activity of α-lipoic 
acid[14,16,17,18,19] and also helps in inhibiting the free radical 
induced endothelial damage and decrease oxidative stress in the 
diabetic individual in whom the antioxidant capacity is defective 
because of active polyol pathway [20]. Distal latency is the most 
frequent measure of F- wave activity. The patients suffering from 
axonal polyneuropathy can be assessed by F-wave procedure that is 
reported as more sensitive and reliable tool [21], but the F-wave 
changes in distal segment of the axon poorly represents the 
therapeutic effect in this method. However, present study 
demonstrates that distal latency was significantly decreased in 
peroneal motor nerve, median motor nerve and ulnar motor nerve. 
In the present study no change was observed in glycaemic control 
with α-lipoic acid supplementation in comparison with control 
group. The present findings are similar to earlier report [22]. 
CONCLUSIONS 
Oral supplementation of α-lipoic acid may be effective in the 
management of diabetic peripheral neuropathy along with oral 
hypoglycaemic agents to improve the motor nerve conduction of 
upper and lower extremity. Alpha-lipoic acid also slows the 
progression of nerve degeneration and improves patient 
compliance. This short period study provide the data about the 
possible clinical effects of α-lipoic acid supplementation on the 
electrophysiological parameters of nerve conduction in type 2 
diabetic peripheral neuropathy patients and provide the base for 
future studies with larger number of patients with at least than one 
year follow up.  
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